A novel perspective on tau in alzheimer's disease

Current Alzheimer Research

Volumn 8, Issue 6, 2011, Pages 639-642

  Bonda, D J ^a   Castellani, R J ^b   Zhu, X ^a   Nunomura, A ^c   Lee, H G ^a   Perry, G ^a,d   Smith, M A ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF YAMANASHI   (Japan)

^d UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

Author keywords

Alzheimer disease; Neuron; Oxidative stress; Phosphorylation; Tau

Indexed keywords

TAU PROTEIN;

ALZHEIMER DISEASE; ARTICLE; HUMAN; NERVE CELL; NEUROFIBRILLARY TANGLE; NEUROPROTECTION; NEUROTOXICITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ALZHEIMER DISEASE; BRAIN; HUMANS; NEUROFIBRILLARY TANGLES; NEURONS; OXIDATIVE STRESS; PHOSPHORYLATION; TAU PROTEINS;

EID: 80051752377     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720511796717131     Document Type: Article

References (61)

1. Terry RD. The Fine Structure of Neurofibrillary Tangles in Alzheimer's Disease. J Neuropathol Exp Neurol 22: 629-642 (1963).
2. Kidd M. Paired helical filaments in electron microscopy of Alzheimer's disease. Nature 197: 192-193 (1963).
3. Tellez-Nagel I, Wisniewski HM. Ultrastructure of neurofibrillary tangles in Steele-Richardson-Olszewski syndrome. Arch Neurol 29: 324-327 (1973).
4. Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem 261: 6084-6089 (1986).
5. Walsh DM, Selkoe DJ. A beta oligomers - a decade of discovery. J Neurochem 101: 1172-1184 (2007).
6. Marx J. Mutation identified as a possible cause of Alzheimer's disease. Science 251: 876-877 (1991).
7. Nash JM. Alzheimer's disease. New insights into its cause lead to new drug strategies. Time 157: 80-81, 85 (2001).
8. Perry G, Raina AK, Cohen ML, Smith MA. When hypotheses dominate. The Scientist 18: 6 (2004).
9. Hernandez F, Avila J. Tauopathies. Cell Mol Life Sci 64: 2219-2233 (2007).
10. Plattner F, Angelo M, Giese KP. The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J Biol Chem 281: 25457-25465 (2006).
11. Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 8: 663-672 (2007).
12. Kidd M. Alzheimer's Disease--an Electron Microscopical Study. Brain 87: 307-320 (1964).
13. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubuleassociated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 83: 4913-4917 (1986).
14. Bancher C, Brunner C, Lassmann H, Budka H, Jellinger K, Wiche G, et al. Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer's disease. Brain Res 477: 90-99 (1989).
15. Braak H, Braak E. Evolution of neuronal changes in the course of Alzheimer's disease. J Neural Transm Suppl 53: 127-140 (1998).
16. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42: 631-639 (1992).
17. Hasegawa M, Smith MJ, Goedert M. Tau proteins with FTDP-17 mutations have a reduced ability to promote microtubule assembly. FEBS Lett 437: 207-210 (1998).
18. Hong M, Zhukareva V, Vogelsberg-Ragaglia V, Wszolek Z, Reed L, Miller BI, et al. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science 282: 1914-1917 (1998).
19. Mori H, Kondo J, Ihara Y. Ubiquitin is a component of paired helical filaments in Alzheimer's disease. Science 235: 1641-1644 (1987).
20. Yan SD, Chen X, Schmidt AM, Brett J, Godman G, Zou YS, et al. Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress. Proc Natl Acad Sci USA 91: 7787-7791 (1994).
21. Ledesma MD, Bonay P, Colaco C, Avila J. Analysis of microtubule- associated protein tau glycation in paired helical filaments. J Biol Chem 269: 21614-21619 (1994).
22. Schweers O, Mandelkow EM, Biernat J, Mandelkow E. Oxidation of cysteine-322 in the repeat domain of microtubule-associated protein tau controls the in vitro assembly of paired helical filaments. Proc Natl Acad Sci USA 92: 8463-8467 (1995).
23. Alonso AD, Zaidi T, Novak M, Barra HS, Grundke-Iqbal I, Iqbal K. Interaction of tau isoforms with Alzheimer's disease abnormally hyperphosphorylated tau and in vitro phosphorylation into the disease-like protein. J Biol Chem 276: 37967-37973 (2001).
24. Alonso AC, Grundke-Iqbal I, Iqbal K. Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat Med 2: 783-787 (1996).
25. Salehi A, Delcroix JD, Mobley WC. Traffic at the intersection of neurotrophic factor signaling and neurodegeneration. Trends Neurosci 26: 73-80 (2003).
26. Ebneth A, Godemann R, Stamer K, Illenberger S, Trinczek B, Mandelkow E. Overexpression of tau protein inhibits kinesindependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer's disease. J Cell Biol 143: 777-794 (1998).
27. Stamer K, Vogel R, Thies E, Mandelkow E, Mandelkow EM. Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J Cell Biol 156: 1051-1063 (2002).
28. Spittaels K, Van den Haute C, Van Dorpe J, Bruynseels K, Vandezande K, Laenen I, et al. Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein. Am J Pathol 155: 2153-2165 (1999).
29. Harada A, Oguchi K, Okabe S, Kuno J, Terada S, Ohshima T, et al. Altered microtubule organization in small-calibre axons of mice lacking tau protein. Nature 369: 488-491 (1994).
30. Elder GA, Friedrich VL, Jr., Bosco P, Kang C, Gourov A, Tu PH, et al. Absence of the mid-sized neurofilament subunit decreases axonal calibers, levels of light neurofilament (NF-L), and neurofilament content. J Cell Biol 141: 727-739 (1998).
31. Rao MV, Houseweart MK, Williamson TL, Crawford TO, Folmer J, Cleveland DW. Neurofilament-dependent radial growth of motor axons and axonal organization of neurofilaments does not require the neurofilament heavy subunit (NF-H) or its phosphorylation. J Cell Biol 143: 171-181 (1998).
32. Cash AD, Aliev G, Siedlak SL, Nunomura A, Fujioka H, Zhu X, et al. Microtubule reduction in Alzheimer's disease and aging is independent of tau filament formation. Am J Pathol 162: 1623-1627 (2003).
33. Smith MA, Richey Harris PL, Sayre LM, Beckman JS, Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci 17: 2653-2657 (1997).
34. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 60: 759-767 (2001).
35. Nunomura A, Perry G, Pappolla MA, Wade R, Hirai K, Chiba S, et al. RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J Neurosci 19: 1959-1964 (1999).
36. Nunomura A, Perry G, Pappolla MA, Friedland RP, Hirai K, Chiba S, et al. Neuronal oxidative stress precedes amyloid-beta deposition in Down syndrome. J Neuropathol Exp Neurol 59: 1011-1017 (2000).
37. Morsch R, Simon W, Coleman PD. Neurons may live for decades with neurofibrillary tangles. J Neuropathol Exp Neurol 58: 188-197 (1999).
38. Takeda A, Smith MA, Avila J, Nunomura A, Siedlak SL, Zhu X, et al. In Alzheimer's disease, heme oxygenase is coincident with Alz50, an epitope of tau induced by 4-hydroxy-2-nonenal modification. J Neurochem 75: 1234-1241 (2000).
39. Wataya T, Nunomura A, Smith MA, Siedlak SL, Harris PL, Shimohama S, et al. High molecular weight neurofilament proteins arephysiological substrates of adduction by the lipid peroxidation product hydroxynonenal. J Biol Chem 277: 4644-4648 (2002).
40. Perez M, Cuadros R, Smith MA, Perry G, Avila J. Phosphorylated, but not native, tau protein assembles following reaction with the lipid peroxidation product, 4-hydroxy-2-nonenal. FEBS Lett 486: 270-274 (2000).
41. Perry G, Taddeo MA, Nunomura A, Zhu X, Zenteno-Savin T, Drew KL, et al. Comparative biology and pathology of oxidative stress in Alzheimer and other neurodegenerative diseases: beyond damage and response. Comp Biochem Physiol C Toxicol Pharmacol 133: 507-513 (2002).
42. Zhu X, Castellani RJ, Takeda A, Nunomura A, Atwood CS, Perry G, et al. Differential activation of neuronal ERK, JNK/SAPK and p38 in Alzheimer disease: the 'two hit' hypothesis. Mech Ageing Dev 123: 39-46 (2001).
43. Zhu X, Raina AK, Perry G, Smith MA. Alzheimer's disease: the two-hit hypothesis. Lancet Neurol 3: 219-226 (2004).
44. Zhu X, Raina AK, Lee HG, Chao M, Nunomura A, Tabaton M, et al. Oxidative stress and neuronal adaptation in Alzheimer disease: the role of SAPK pathways. Antioxid Redox Signal 5: 571-576 (2003).
45. Zhu X, Raina AK, Rottkamp CA, Aliev G, Perry G, Boux H, et al. Activation and redistribution of c-Jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease. J Neurochem 76: 435-441. (2001).
46. Shoji M, Iwakami N, Takeuchi S, Waragai M, Suzuki M, Kanazawa I, et al. JNK activation is associated with intracellular betaamyloid accumulation. Brain Res Mol Brain Res 85: 221-233 (2000).
47. Zhu X, Raina AK, Perry G, Smith MA. Apoptosis in Alzheimer disease: a mathematical improbability. Curr Alzheimer Res 3: 393-396 (2006).
48. Raina AK, Hochman A, Zhu X, Rottkamp CA, Nunomura A, Siedlak SL, et al. Abortive apoptosis in Alzheimer's disease. Acta Neuropathol (Berl) 101: 305-310 (2001).
49. Zhu X, Wang Y, Ogawa O, Lee HG, Raina AK, Siedlak SL, et al. Neuroprotective properties of Bcl-w in Alzheimer disease. J Neurochem 89: 1233-1240 (2004).
50. Perry G, Nunomura A, Lucassen P, Lassmann H, Smith MA. Apoptosis and Alzheimer's disease. Science 282: 1268-1269 (1998).
51. Perry G, Zhu X, Smith MA. Do neurons have a choice in death? Am J Pathol 158: 1-2 (2001).
52. Lee HG, Perry G, Moreira PI, Garrett MR, Liu Q, Zhu X, et al. Tau phosphorylation in Alzheimer's disease: pathogen or protector? Trends Mol Med 11: 164-169 (2005).
53. Smith MA, Casadesus G, Joseph JA, Perry G. Amyloid-beta and tau serve antioxidant functions in the aging and Alzheimer brain. Free Radic Biol Med 33: 1194-1199 (2002).
54. Zhu X, Castellani RJ, Takeda A, Nunomura A, Atwood CS, Perry G, et al. Differential activation of neuronal ERK, JNK/SAPK and p38 in Alzheimer disease: the 'two hit' hypothesis. Mech Ageing Dev 123: 39-46 (2001).
55. Zhu X, Rottkamp CA, Boux H, Takeda A, Perry G, Smith MA. Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease. J Neuropathol Exp Neurol 59: 880-888. (2000).
56. Atzori C, Ghetti B, Piva R, Srinivasan AN, Zolo P, Delisle MB, et al. Activation of the JNK/p38 pathway occurs in diseases characterized by tau protein pathology and is related to tau phosphorylation but not to apoptosis. J Neuropathol Exp Neurol 60: 1190-1197 (2001).
57. Hensley K, Floyd RA, Zheng NY, Nael R, Robinson KA, Nguyen X, et al. p38 kinase is activated in the Alzheimer's disease brain. J Neurochem 72: 2053-2058 (1999).
58. Ferrer I, Blanco R, Carmona M, Puig B. Phosphorylated mitogenactivated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies. J Neural Transm 108: 1397-1415 (2001).
59. Pei JJ, Braak H, An WL, Winblad B, Cowburn RF, Iqbal K, et al. Up-regulation of mitogen-activated protein kinases ERK1/2 and MEK1/2 is associated with the progression of neurofibrillary degeneration in Alzheimer's disease. Brain Res Mol Brain Res 109: 45-55 (2002).
60. Pei JJ, Braak E, Braak H, Grundke-Iqbal I, Iqbal K, Winblad B, et al. Localization of active forms of C-jun kinase (JNK) and p38 kinase in Alzheimer's disease brains at different stages of neurofibrillary degeneration. J Alzheimers Dis 3: 41-48 (2001).
61. Hartzler AW, Zhu X, Siedlak SL, Castellani RJ, Avila J, Perry G, et al. The p38 pathway is activated in Pick disease and progressive supranuclear palsy: a mechanistic link between mitogenic pathways, oxidative stress, and tau. Neurobiology of Aging 23: 855-859 (2002).